tonkinecin | 174819-52-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: tonkinecin
• 英文别名: (2S)-4-[(3S,15R)-3,15-dihydroxy-15-[(2R,5R)-5-[(1R)-1-hydroxytridecyl]oxolan-2-yl]pentadecyl]-2-methyl-2H-furan-5-one
• CAS: 174819-52-4
• 化学式: C₃₇H₆₈O₆
• 分子量: 608.943
• InChiKey: BJNHGCXQPCYJLU-CXPQHEJVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.2
• 重原子数：
  43
• 可旋转键数：
  28
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  96.2
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (1''R,2R,2'R,5R)-2-<1''-(Methoxymethoxy)tridecyl>-5-(oxiran-2'-yl)tetrahydrofuran 在 bis-triphenylphosphine-palladium(II) chloride copper(l) iodide 、 正丁基锂 、 二甲基硫 、 三氟化硼乙醚 、 四丁基氟化铵 、 sodium acetate 、 三乙胺 、 N,N-二异丙基乙胺 、 对甲苯磺酰肼 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 tonkinecin
  参考文献：
  名称：

  The First Synthesis of Tonkinecin, an Annonaceous Acetogenin with a C-5 Carbinol Center

  摘要：

  [GRAPHICS]Reported herein is the first synthetic approach to tonkinecin (1) which uses a palladium catalyzed cross-coupling reaction between the tetrahydrofuran unit (4) and the butenolide (3) as the key step for constructing the backbone of 1, The stereogenic centers at C-5, C-21, C-22, and C-36 were derived from D-xylose, D-glucose, and L-lactate, respectively, whereas those at C-17, and C-18 were generated using Sharpless asymmetric dihydroxylation.

  DOI：

  10.1021/ol990062y

文献信息

• Enantioselective Syntheses of Monotetrahydrofuran Annonaceous Acetogenins Tonkinecin and Annonacin Starting from Carbohydrates
  作者：Tai-Shan Hu、Qian Yu、Yu-Lin Wu、Yikang Wu

  DOI：10.1021/jo005643b

  日期：2001.2.1

  The total synthesis of two mono-THF acetogenins, tonkinecin (1) and annonacin (2), is reported in full detail. Terminal acetylene 3 prepared from D-glucono-delta-lactone and asymmetric dihydroxylation was employed as a common intermediate for both targets 1 and 2. Pd(0)-catalyzed coupling reaction of 3 with vinyl iodides 4 and 5, the chiral centers of which were taken from D-xylose and S-(-)-ethyl

  详细报道了两种单-THF产乙酸素，唐宁霉素（1）和番农苷（2）的总合成。由D-葡萄糖酸-δ-内酯和不对称二羟基化反应制得的末端乙炔3被用作靶1和2的通用中间体。Pd（0）催化3与乙烯基碘4和5的偶联反应，其手性中心分别从D-木糖和S-（-）-乙基乳酸中提取，分别得到烯炔26和27。用二酰亚胺对26或27进行选择性氢化，然后除去MOM醚，从而完成了1的合成。在三氟化硼醚化物的存在下，3的锂衍生物与环氧化物6之间的偶联反应得到42。在环氧化物6中获得了两个手性中心来自L-抗坏血酸。随后的催化加氢和MOM保护得到43b。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• TUBULIN BINDING COMPOUNDS (COBRA)
  申请人：Parker Hughes Institute

  公开号：EP1091948B9

  公开（公告）日：2003-09-10
• The First Synthesis of Tonkinecin, an Annonaceous Acetogenin with a C-5 Carbinol Center
  作者：Tai-Shan Hu、Qian Yu、Qi Lin、Yu-Lin Wu、Yikang Wu

  DOI：10.1021/ol990062y

  日期：1999.8.1

  [GRAPHICS]Reported herein is the first synthetic approach to tonkinecin (1) which uses a palladium catalyzed cross-coupling reaction between the tetrahydrofuran unit (4) and the butenolide (3) as the key step for constructing the backbone of 1, The stereogenic centers at C-5, C-21, C-22, and C-36 were derived from D-xylose, D-glucose, and L-lactate, respectively, whereas those at C-17, and C-18 were generated using Sharpless asymmetric dihydroxylation.